scholarly journals MOLECULAR TYPING OF Candida albicans ISOLATES FROM HOSPITALIZED PATIENTS

2013 ◽  
Vol 55 (6) ◽  
pp. 385-391 ◽  
Author(s):  
Patricia de Souza Bonfim-Mendonca ◽  
Adriana Fiorini ◽  
Cristiane Suemi Shinobu-Mesquita ◽  
Lilian Cristiane Baeza ◽  
Maria Aparecida Fernandez ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Blood Culture ◽  
Genetic Variability ◽  
Molecular Typing ◽  
Fungal Infections ◽  
Common Origin ◽  
High Similarity ◽  
Candida Spp ◽  
Typing Methods ◽  
A Site

SUMMARY Introduction: The majority of nosocomial fungal infections are caused by Candida spp. where C. albicans is the species most commonly identified. Molecular methods are important tools for assessing the origin of the yeasts isolated in hospitals. Methods: This is a study on the genetic profifiles of 39 nosocomial clinical isolates of C. albicans using two typing methods: random amplifified polymorphic DNA (RAPD) and microsatellite, two different primers for each technique were used. Results: RAPD provided 10 and 11 different profiles with values for SAB of 0.84 ± 0.126 and 0.88 ± 0.08 for primers M2 and P4, respectively. Microsatellite using two markers, CDC3 and HIS3, allowed the observation of six and seven different alleles, respectively, with combined discriminatory power of 0.91. Conclusions: Although genetic variability is clear, it was possible to identify high similarity, suggesting a common origin for at least a part of isolates. It is important to emphasize that common origin was proven from yeasts isolated from colonization (urine, catheter or endotracheal secretions) and blood culture from the same patient, indicating that the candidemia must have started from a site of colonization. The combination of RAPD and microsatellite provides a quick and efficient analysis for investigation of similarity among nosocomial isolates of C. albicans.

ROSEOFUNGIN-AS, OINTMENT 2% FOR TREATMENT OF TINEA PEDIS AND TINEA CORPORIS: RESULTS OF A RANDOMIZED, BLINDED, PROSPECTIVE, MULTICENTER PHASE III CLINICAL TRIAL

2021 ◽  
pp. 29-39
Author(s):  
А.К. САДАНОВ ◽  
В.Э. БЕРЕЗИН ◽  
И.Р. КУЛМАГАМБЕТОВ ◽  
Л.П. ТРЕНОЖНИКОВА ◽  
А.С. БАЛГИМБАЕВА
Keyword(s):  
Clinical Trial ◽  
Candida Albicans ◽  
Tinea Pedis ◽  
Fungal Infections ◽  
Tinea Corporis ◽  
Phase Iii ◽  
Microsporum Canis ◽  
Candida Spp ◽  
Reference Drug ◽  
Phase Iii Clinical Trial

Розеофунгин-АС, мазь 2% для наружного применения разработана для лечения микозов кожи разной этиологии, вызванных дерматофитными, дрожжеподобными и плесневыми грибами. Многоцентровое слепое проспективное рандомизированное исследование проводили в Республике Казахстан для сравнения терапевтической эффективности и безопасности препаратов «Розеофунгин-АС, мазь 2%» и «Клотримазол, крем 1%» при лечении tinea pedis и tinea corporis. Препараты применяли 2 раза в день в течение 28 дней. Лабораторные общеклинические и биохимические обследования пациентов проводили на 0, 14 и 28 дни исследования. Микологическое обследование включало микроскопические и культуральные исследования, которые проводились до лечения и на 28-30-й день после окончания лечения. В клиническое исследование III фазы входили 410 пациентов, включая 290 пациентов с tinea pedis и 120 пациентов с tinea corporis. Лечение препаратом «Розеофунгин-АС, мазь 2%» получали 310 пациентов, лечение препаратом «Клотримазол, крем 1%» - 100 пациентов. У больных обеих групп уже на 14 день уменьшалась выраженность субъективных и объективных проявлений. К 28 дню практически все клинические признаки патологического процесса отсутствовали. Совокупная клинико-микологическая эффективность препарата «Розеофунгин-АС, мазь 2%» составила 99,1%, препарата «Клотримазол, крем 1%» - 98,0%. Препарат «Розеофунгин-АС, мазь 2%» проявил высокую эффективность при лечении грибковых инфекций tinea pedis и tinea corporis, вызванных возбудителями трихофитии (Trihophyton rubrum, T. violarum, T. tonsurans), микроспории (Microsporum canis, M. gypseum), кандидоза (Candida albicans, Candida spp.), плесневыми грибами (Penicillium glaucum). В исследовании не были зафиксированы аллергические реакции и индивидуальная непереносимость исследуемого и референтного препаратов. Препарат «Розеофунгин-АС, мазь 2%» является эффективным антимикотическим средством, клинико-микологическая эффективность которого в терапии микозов кожи составляет 99,1%. Препарат имеет высокий уровень переносимости, безопасности и приемлемости RoseofunginAS, ointment 2% for external use was developed for the treatment of skin mycoses of various etiologies caused by dermatophytic and yeastlike fungi and molds. A multicenter, blind, prospective, randomized trial was conducted in the Republic of Kazakhstan to compare the therapeutic effectiveness and safety of RoseofunginAS, ointment 2% and Clotrimazole, cream 1% in the treatment of tinea pedis and tinea corporis. The drugs were administered twice daily for 28 days. Laboratory general clinical and biochemical examinations of patients were performed on days 0, 14, and 28 of the trial. Mycological examination included microscopic and cultural studies, which were carried out before treatment and on days 2830 after the end of treatment. The Phase III clinical trial involved 410 patients, including 290 with tinea pedis and 120 with tinea corporis. Treatment with RoseofunginAS, ointment 2% was administered to 310 patients, 100 patients were treated with Clotrimazole, cream 1%. In patients of both groups, the severity of subjective and objective manifestations decreased already on day 14. By day 28, almost all clinical signs of the pathological process were absent. The cumulative clinical and mycological effectiveness of the drug RoseofunginAS, ointment 2% was 99.1% and that of the drug Clotrimazole, cream 1% reached 98.0%. The drug RoseofunginAS, ointment 2% exhibited high effectiveness in the treatment of fungal infections, including tinea pedis and tinea corporis, with pathogens that cause trichophytosis (Trihophyton rubrum, T. violarum, T. tonsurans), microsporia (Microsporum canis, M. gypseum), candidiasis (Candida albicans, Candida spp.), and molds (Penicillium glaucum). The study did not record allergic reactions and individual intolerance to the study and reference drug. The drug RoseofunginAS, ointment 2% is an effective antimycotic agent, the clinical and mycological effectiveness of which in the treatment of skin mycoses was 99.1%. The drug possesses a high level of tolerance, safety and acceptability.

scholarly journals Comparison of molecular typing methods for Candida albicans.

1992 ◽  
Vol 30 (10) ◽  
pp. 2674-2679 ◽  
Author(s):  
P T Magee ◽  
L Bowdin ◽  
J Staudinger
Keyword(s):  
Candida Albicans ◽  
Molecular Typing ◽  
Typing Methods

Invasive Fungal Infection in Febrile Patients with Hematologic Malignancies Undergoing Chemotherapy in Iran

2019 ◽  
Vol 19 (3) ◽  
pp. 302-307 ◽  
Author(s):  
Saba Sheikhbahaei ◽  
Alireza Mohammadi ◽  
Roya Sherkat ◽  
Alireza Emami Naeini ◽  
Majid Yaran ◽  
...  
Keyword(s):  
Blood Culture ◽  
Antifungal Therapy ◽  
Fungal Infections ◽  
Hematologic Malignancy ◽  
Hematologic Malignancies ◽  
Fungal Species ◽  
Antifungal Prophylaxis ◽  
Invasive Fungal Infections ◽  
Severe Neutropenia ◽  
Candida Spp

Background: Patients with hematological malignancies undergoing cytotoxic chemotherapy are susceptible to develop invasive fungal infections particularly Aspergillus and Candida spp. Early detection of these infections is required to start immediate antifungal therapy and increase the survival of these patients. Method: Our study included consecutive patients of any age with hematologic malignancies who were hospitalized to receive chemotherapy and suffer from persistent fever (rectal temperature >38.5°C) for more than 5 days despite receiving broad-spectrum antibiotics. A whole blood sample was taken and sent for blood culture. PCR was also conducted for Aspergillus and Candida species. Results: One hundred and two patients were investigated according to the inclusion criteria. The most common hematologic malignancy was AML affecting 38 patients (37.2%). Six patients were diagnosed with invasive fungal infections (A. fumigatus n=3, C. albicans n=2, A. flavus n=1) by PCR (5.8%) while blood culture showed fungus only in 1 patient. Three more cases were known as probable IFI since they responded to antifungal therapy but the PCR result was negative for them. AML was the most prevalent malignancy in IFI patients (83.3%) and odds ratio for severing neutropenia was 21.5. Odds for each of the baseline characteristics of patients including gender, age>60, diabetes mellitus, previous IFI, history of using more than 3 antibiotics, antifungal prophylaxis, episodes of chemotherapy> 8 and chemotherapy regimen of daunarubicin+cytarabine were calculated. Conclusion: We found that multiplex real-time PCR assay is more accurate than blood culture in detecting fungal species and the results are prepared sooner. Among all factors, the only type of cancer (AML) and severe neutropenia, were found to be risk factors for the development of fungal infections in all hematologic cancer patients and previous IFI was a risk factor only AML patients.

scholarly journals The In Vitro Potential of 1-(1H-indol-3-yl) Derivatives against Candida spp. and Aspergillus niger as Tyrosinase Inhibitors

2021 ◽  
Vol 9 (10) ◽  
pp. 2070
Author(s):  
Teresa Gervasi ◽  
Giovanna Ginestra ◽  
Francesca Mancuso ◽  
Davide Barreca ◽  
Laura De Luca ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Aspergillus Niger ◽  
Fungicidal Activity ◽  
Candida Parapsilosis ◽  
Fungal Infections ◽  
Clinical Isolates ◽  
Candida Spp ◽  
Antifungal Potential ◽  
Tyrosinase Inhibitors

Given the increased antimicrobial resistance, global effort is currently focused on the identification of novel compounds, both of natural and chemical origin. The present study reports on the antifungal potential of 1-(1H-indol-3-yl) derivatives, previously known as tyrosinase inhibitors. The effect of seven compounds (indicated as 3a–g) was determined against Candida albicans ATCC 10531, three clinical isolates of Candida albicans, two clinical isolates of Candida glabrata, two clinical isolates of Candida parapsilosis and Aspergillus niger ATCC 16404. The effect of these derivatives on tyrosinase enzymatic activity was also evaluated. Results showed a fungicidal activity of compounds 3b, 3c and 3e against all tested strains at concentrations ranging between 0.250 and 1 mg/mL. Furthermore, the association between 3c and fluconazole and between 3b and caspofungin showed a trend of indifference tending toward synergism. Compound 3c was also able to inhibit microbial tyrosinase up to ~28% at the concentration of 0.250 mg/mL. These data could help provide novel therapeutics for topical use to treat fungal infections and increase the potential effectiveness of the association between novel compounds and commercial antifungals in order to combat drug resistance.

Detection of Antifungal Properties in Lactobacillus paracasei subsp. paracasei SM20, SM29, and SM63 and Molecular Typing of the Strains

2005 ◽  
Vol 68 (1) ◽  
pp. 111-119 ◽  
Author(s):  
SUSANNE MIESCHER SCHWENNINGER ◽  
UELI VON AH ◽  
BRIGITTE NIEDERER ◽  
MICHAEL TEUBER ◽  
LEO MEILE
Keyword(s):  
Molecular Typing ◽  
Raw Milk ◽  
Rrna Gene ◽  
Sequencing Analysis ◽  
Candida Spp ◽  
Food And Feed ◽  
Carbohydrate Fermentation ◽  
Typing Methods ◽  
Raw Milk Cheese ◽  
Species Specific

Lactobacilli isolated from different food and feed samples such as raw milk, cheese, yoghurt, olives, sour dough, as well as corn and grass silage, were screened for their antifungal activities. Out of 1,424 isolates tested, 82 were shown to be inhibitory to different yeasts (Candida spp. and Zygosaccharomyces bailii) and a Penicillium sp., which were previously isolated from spoiled yoghurt and fruits. Carbohydrate fermentation patterns suggested that a substantial portion, 25%, belonged to the Lactobacillus casei group, including L. casei, L. paracasei, and L. rhamnosus. The isolates SM20 (DSM14514), SM29 (DSM14515), and SM63 (DSM14516) were classified by PCR using species-specific primers to target the corresponding type strains (L. casei, L. paracasei, and L. rhamnosus) as controls. Further molecular typing methods such as randomly amplified polymorphic DNA, pulsed-field gel electrophoresis, and sequencing analysis of the 16S rRNA gene allowed classifying strains SM20, SM29, and SM63 as L. paracasei subsp. paracasei in accordance with the new reclassification of the L. casei group proposed by Collins et al. (Int. J. Syst. Bacteriol. 39:105–108).

scholarly journals Comparison of four molecular typing methods to assess genetic relatedness of Candida albicans clinical isolates in Taiwan

2005 ◽  
Vol 54 (3) ◽  
pp. 249-258 ◽  
Author(s):  
Kuo-Wei Chen ◽  
Hsiu-Jung Lo ◽  
Yu-Hui Lin ◽  
Shu-Ying Li
Keyword(s):  
Candida Albicans ◽  
Molecular Typing ◽  
Genetic Relatedness ◽  
Geographic Origin ◽  
Discriminatory Power ◽  
Patient Specific ◽  
High Discriminatory Power ◽  
Typing Methods ◽  
Pcr Method ◽  
Genetic Profiles

This report describes the investigation of the genetic profiles of 53 Candida albicans isolates collected from 18 hospitals in Taiwan using three PFGE-based typing methods (PFGE karyotyping, and PFGE of SfiI and BssHII restriction fragments) and one repetitive-sequence-PCR (rep-PCR) method. All four methods were able to identify clonal related isolates from the same patients. PFGE-BssHII exhibited the highest discriminatory power by discriminating 40 genotypes, followed by PFGE-SfiI (35 genotypes) and then by rep-PCR (31 genotypes), while PFGE karyotyping exhibited the lowest discriminatory power (19 genotypes). High discriminatory power can also be achieved by combining typing methods with different typing mechanisms, such as rep-PCR and PFGE-based typing methods. The results also showed that the genotype of each isolate was patient-specific and not associated with the source of the isolation, geographic origin or antifungal resistance.

scholarly journals Candidemia and its Risk Factors in Neonates and Children

2020 ◽  
Vol 8 (4) ◽  
Author(s):  
Azam Fattahi ◽  
Ensieh Lotfali ◽  
Hossein Masoumi-Asl ◽  
Shirin Sayyahfar ◽  
Majid Kalani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Candida Albicans ◽  
Blood Culture ◽  
Candida Glabrata ◽  
Candida Parapsilosis ◽  
Species Level ◽  
Candida Spp ◽  
Pcr Rflp ◽  
Candida Parapsilosis Complex ◽  
Isolated Species

Objectives: The present study was conducted to raise attention to the frequency of Candida spp. and evaluation of risk factors of candidemia in hospitalized neonates and children. Methods: Identification of Candida at species level was done using the PCR-RFLP method. The Candida albicans complex and Candida parapsilosis complex were differentiated using the HWP1 gene amplification and PCR-RFLP with NlaIII restriction enzyme, respectively. Results: Out of 75 blood culture specimens, 42 (84%) cases were positive for Candida spp. of whom 30 (71.42%) and 12 (28.57%) cases were female and male, respectively. Thirty-two (76%) candidemia were presented in pediatrics with 6 years up to 12 years, 10 (23.80%) in neonates of one month or less. In the present study, Candida parapsilosis (n =25; 59.52%) was the most prevalent isolated species followed by C. albicans (n =11; 26.19%), C. tropicalis (n =4; 9.52%), and Candida glabrata (n =2; 4.76%). Conclusions: According to potentially dangerous complications of bloodstream infection by Candida spp. in neonates and children, it is necessary to identify and eliminate the underlying conditions and risk factors of this disease.

scholarly journals Diagnosis and treatment of mucosa Candida spp. infections – a review article

2019 ◽  
Vol 73 (1) ◽  
pp. 61 ◽  
Author(s):  
Marta Dąbrowska ◽  
Monika Sienkiewicz ◽  
Paweł Kwiatkowski ◽  
Michał Dąbrowski
Keyword(s):  
Drug Resistance ◽  
Candida Albicans ◽  
Fungal Infections ◽  
Opportunistic Pathogen ◽  
Review Article ◽  
Immune Disorders ◽  
Candida Spp ◽  
Common Cause ◽  
Invasive Infections ◽  
Systemic Infections

<p>Candida albicans is the most common cause of fungal infections worldwide. Non-albicans Candida species play an important role in vulvovaginal candidiasis and invasive infections. Most cases of infections are endogenous. In case of patients with immune disorders this opportunistic pathogen causes both surface, systemic infections, and candidemia. Symptoms depend on the area affected. Candidiasis are treated with antimycotics; these include clotrimazole, nystatin, fluconazole, voriconazole, amphotericin B, and echinocandins. The emergence of drug resistance and the side effects of currently available antifungals are becoming a major problem in the management of Candida spp. infection.</p>

Sign in / Sign up

Export Citation Format

Share Document